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Background: Nutritional parameters represent modifiable factors
to improve outcomes after HSCT. Pediatric studies linking weight
to survival are over 10 years old, and analyses of prealbumin (PAB)
levels have not examined the impact on survival.
Methods:We conducted a retrospective chart review of all pediatric
HSCT at our institution from 7/1/2007 to 6/30/2011 (N5 77).Wil-
coxon rank-sum test was used to compare weight characteristics as
well as PAB and albumin levels (admission, days 0, +7, +14,+28,
and +90 for albumin alone) between the autologous (auto) and allo-
geneic (allo) groups. Survival analyses utilized the Kaplan-Meier
method and the log-rank test to compare differences. Effects on sur-
vival were examined with a Cox proportional hazards model and
analyses of non-relapse mortality (NRM) incorporated competing
risks.
Results: Mean weights as % of ideal body weight at admission
were above 100% and not significantly different between the auto
and allo groups (p 5 0.80). BMI at admission was not significantly
different between the auto and allo groups (19.5 and 19.3 respec-
tively, p 5 0.97). At day +30, the auto group had greater % weight
loss than the allo group with mean weight loss of 1.7% (p 5 0.01).
In the auto group, weight loss at day +30 was associated with sig-
nificantly worse day +100 and 1 yr survival compared to those who
had weight gain (p 5 0.03). The lowest median PAB level was 13.8
mg/dL on day 0 for allo patients and 12.2 mg/dL on day +7 for
auto patients. Similarly, the lowest median albumin level was 2.9
g/dL on day 0 for allo patients and 2.8 g/dL on day +7 for auto pa-
tients. Differences between groups at these time points were statis-
tically significant (p\0.05). Univariate analyses identified PAB
levels below 15 mg/dL at day +7 as significantly decreasing day
+100 and 1 yr survival in the allo group (p 5 0.0003). Additionally,
allo patients with a PAB level below 12 mg/dL at any time between
day 0 to +14 had worse day +100 and 1 yr survival (p 5 0.023).
Multivariate analysis of the combined groups demonstrated a signif-
icant impact of decreased PAB levels between day 0 to +14 on
NRM, with a hazard ratio of 0.85 (95%CI 0.76-0.96, p 5 0.006).
Accordingly, this represents an increase in NRM risk of 120%
per 5 mg/dL decrease in PAB.
Conclusion: Nutritional support should be maximized early in the
transplant course. As PAB is decreased in the setting of inflamma-
tion, future studies should prospectively evaluate PAB in conjunction
with inflammatory markers.276
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Patient
Presenting Symptoms
of Initial CNS Event
Age at Diagnosis of
Moyamoya Syndrome Age at EDA
1 Seizures 11 years 6 months 12 years 2 mont
2 Visual changes 13 years 2 months Two-Step Proced
4 months and
3 Seizures 2 years 6 months 4 years 6 month
4 Left-Sided Hemiparesis 3 years 6 years 6 month
5 Seizures, Personality
Changes
7 years 6 months Two-Step Proced
years 10 mon
years 11 mon
6 Eye pain 6 years 11 years 9 montBackground: Patients with sickle cell disease (SCD) have a high risk
of intracranial large vessel vasculopathy, leading to a proliferation of
microvasculature at the base of the brain known as moyamoya syn-
drome. This confers a high risk of intraventricular hemorrhage
and permanent neurologic deficits. Moyamoya syndrome can be
treated surgically with a revascularization procedure called encepha-
loduroarteriosynangiosis (EDAS), which has been shown to decrease
but not eliminate the risk of stroke. Hematopoietic cell transplanta-
tion (HCT) from a compatible sibling is the most effective way of
preventing central nervous system (CNS) complications in SCD pa-
tients at risk for CNS events. There have been several reports of pa-
tients with SCD and moyamoya syndrome undergoing EDAS
successfully; however, there have been no reports of these patients
undergoing EDAS followed by HCT.
Results:We report six pediatric cases of patients with SCDwho de-
veloped moyamoya syndrome, all of whom underwent EDAS fol-
lowed by HCT. All patients underwent EDAS procedure
successfully. One patient experienced a stroke less than a month after
EDAS. Another patient developed a foot-drop post-EDAS, though
imaging did not show any new areas of infarct. All patients under-
went HLA-matched sibling-donor HCT. The chronic transfusion
therapy was successfully discontinued in the two patients who had
been on it prior to treatment. Post-transplant, one patient developed
seizures, with imaging consistent with possible infarct; the patient
was placed on antiepileptics and has not had subsequent seizures.
In all follow-up imaging, there has been no progression of the pa-
tients’ moyamoya syndrome.
Conclusion:These are the first reported cases of EDAS successfully
followed by HCT in patients with SCD and moyamoya syndrome.
Five of the six patients had no further CNS events, and all remained
neurologically stable, with no progression of their moyamoya syn-
drome. HCT is the standard of care in patients with SCD at risk
for CNS complications, leading to excellent stroke-free survival
rates. Patients with moyamoya syndrome and SCD are at high risk
of developing CNS complications. Transplant-eligible SCD pa-
tients who develop moyamoya syndrome may benefit from EDAS
prior to HCT in order to minimize CNS complications. Further in-
vestigation by way of an international, multicenter prospective study
is needed to determine the long-term outcome and potential benefits
of this therapeutic combination.277
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MATCHED UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANS-
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Liney, D.1, Lee,M.A.2, Sun, P.1, London,W.B.1, Lehmann, L.E.2 1Dana
Farber Cancer Institute, Boston, MA; 2Dana- Farber/Children’s Hospital
Cancer Care, Boston, MA
It is well understood that undergoing hematopoietic stem cell
transplant (HSCT) froman unrelated (URD) compared to amatched
sibling donor (MSD) results in increased graft versus host disease
(GVHD) and for the pediatric population this often but not always
negatively impacts overall survival. In the current era of high resolu-
tion Class I / Class II typing there is a lack of clarity about the impactS Procedure Age at HCT Post-HCT Complications
hs 12 years 8 months Seizure, Possible Left Middle
Cerebral Artery Infarct
ure: 13 years
13 years 7 months
13 years 9 months None
s 5 years 6 months None
s 8 years 6 months None
ure: 8
ths and 8
ths
13 years None
hs 13 years 6 months None
